Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The whole world now is directed to implement strategies that enhance the patient's quality of
life and prevent tumor relapse.
Enhanced recovery after pancreatic surgery (ERAPS) program was found to improve the quality
of life as it is an evidence-based protocol designed to standardize and optimize
perioperative medical care in order to reduce surgical trauma, perioperative physiological
stress, organ dysfunction, reduction of clinical complications, length of hospital stay and
the health costs together with increase of patient satisfaction.
lidocaine; it is an amide local anaesthetic Recently its use as intravenous perioperative
infusion for abdominal cancer surgeries is encouraging, as it significantly reduces
postoperative pain, opioid consumption and nausea and vomiting. it also promotes
gastrointestinal function recovery, and shortens the postoperative hospital stay. In
addition, lidocaine in particular can act directly and indirectly on pancreatic cancer cells
and the tumor microenvironment.
The investigators suggest that IV lidocaine infusion in combination with ERAPS protocol may
achieve better postoperative outcomes after pancreatic surgery for cancer.